Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2019 Jan 10;176(1-2):404. doi: 10.1016/j.cell.2018.12.034. No abstract available.

PMID:
30633907
2.

Heterogeneous Responses of Hematopoietic Stem Cells to Inflammatory Stimuli Are Altered with Age.

Mann M, Mehta A, de Boer CG, Kowalczyk MS, Lee K, Haldeman P, Rogel N, Knecht AR, Farouq D, Regev A, Baltimore D.

Cell Rep. 2018 Dec 11;25(11):2992-3005.e5. doi: 10.1016/j.celrep.2018.11.056.

3.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038. Erratum in: Cell. 2019 Jan 10;176(1-2):404.

PMID:
30388456
4.

Early Trajectory Prediction in Elite Athletes.

Owens CB, de Boer C, Gennari G, Broersen R, Pel JJ, Miller B, Clapp W, van der Werf YD, De Zeeuw CI.

Cerebellum. 2018 Dec;17(6):766-776. doi: 10.1007/s12311-018-0975-9.

5.

Thinking-While-Moving Exercises May Improve Cognition in Elderly with Mild Cognitive Deficits: A Proof-of-Principle Study.

de Boer C, Echlin HV, Rogojin A, Baltaretu BR, Sergio LE.

Dement Geriatr Cogn Dis Extra. 2018 Jul 11;8(2):248-258. doi: 10.1159/000490173. eCollection 2018 May-Aug.

6.

BROCKMAN: deciphering variance in epigenomic regulators by k-mer factorization.

de Boer CG, Regev A.

BMC Bioinformatics. 2018 Jul 3;19(1):253. doi: 10.1186/s12859-018-2255-6.

7.

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.

Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal JJ, Hauke R, Tutrone RF, Saleh M, Chow Maneval E, Thomas S, Ricci DS, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI, Antonarakis ES.

Ann Oncol. 2017 Sep 1;28(9):2264-2271. doi: 10.1093/annonc/mdx283.

8.

"That Landscape Is Where I'd Like to Be … ": Offering Patients With Cancer a Choice of Artwork.

George DR, de Boer C, Green MJ.

JAMA. 2017 Mar 7;317(9):890-892. doi: 10.1001/jama.2017.1233. No abstract available.

PMID:
28267834
9.

Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.

Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI.

Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. doi: 10.1158/1078-0432.CCR-16-2509. Epub 2017 Feb 17.

10.
11.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG.

Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.

12.

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE.

Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6.

13.

Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML.

Puram RV, Kowalczyk MS, de Boer CG, Schneider RK, Miller PG, McConkey M, Tothova Z, Tejero H, Heckl D, Järås M, Chen MC, Li H, Tamayo A, Cowley GS, Rozenblatt-Rosen O, Al-Shahrour F, Regev A, Ebert BL.

Cell. 2016 Apr 7;165(2):303-16. doi: 10.1016/j.cell.2016.03.015.

14.

Natural variation in non-coding regions underlying phenotypic diversity in budding yeast.

Salinas F, de Boer CG, Abarca V, García V, Cuevas M, Araos S, Larrondo LF, Martínez C, Cubillos FA.

Sci Rep. 2016 Feb 22;6:21849. doi: 10.1038/srep21849.

15.

Prostate Cancer Burden at the Uganda Cancer Institute.

Okuku F, Orem J, Holoya G, De Boer C, Thompson CL, Cooney MM.

J Glob Oncol. 2016 Feb 17;2(4):181-185. doi: 10.1200/JGO.2015.001040. eCollection 2016 Aug.

16.

Placebo and Nocebo Effects in Sexual Medicine: An Experimental Approach.

Kruger TH, Grob C, de Boer C, Peschel T, Hartmann U, Tenbergen G, Schedlowski M.

J Sex Marital Ther. 2016 Nov 16;42(8):721-739. Epub 2016 Jan 19.

PMID:
26786495
17.

Perceived barriers to and facilitators of labor market engagement for individuals with chronic physical illness in their experience with disability policy: a systematic review of qualitative evidence protocol.

Small S, de Boer C, Swab M.

JBI Database System Rev Implement Rep. 2016 Jan 15;13(12):59-69. doi: 10.11124/jbisrir-2015-2493. No abstract available.

PMID:
26767816
18.

Delays in Manual Reaching Are Associated with Impaired Functional Abilities in Early Dementia Patients.

de Boer C, Pel JJ, van der Steen J, Mattace-Raso F.

Dement Geriatr Cogn Disord. 2015;40(1-2):63-71. doi: 10.1159/000377674. Epub 2015 Jun 3.

PMID:
26043721
19.

The Effect of Neurodegeneration on Visuomotor Behavior in Alzheimer's Disease and Parkinson's Disease.

de Boer C, van der Steen J, Mattace-Raso F, Boon AJ, Pel JJ.

Motor Control. 2016 Jan;20(1):1-20. doi: 10.1123/mc.2014-0015. Epub 2015 Feb 12.

PMID:
25675275
20.

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma.

von Tresckow B, Morschhauser F, Ribrag V, Topp MS, Chien C, Seetharam S, Aquino R, Kotoulek S, de Boer CJ, Engert A.

Clin Cancer Res. 2015 Apr 15;21(8):1843-50. doi: 10.1158/1078-0432.CCR-14-1845. Epub 2015 Jan 27.

21.

Guidelines for feeding very low birth weight infants.

Dutta S, Singh B, Chessell L, Wilson J, Janes M, McDonald K, Shahid S, Gardner VA, Hjartarson A, Purcha M, Watson J, de Boer C, Gaal B, Fusch C.

Nutrients. 2015 Jan 8;7(1):423-42. doi: 10.3390/nu7010423. Review.

22.

Towards a behavioral vaccine: exposure to accessible temptation when self-regulation is endorsed enhances future resistance to similar temptations in children.

de Boer C, de Ridder D, de Vet E, Grubliauskiene A, Dewitte S.

Appl Psychol Health Well Being. 2015 Mar;7(1):63-84. doi: 10.1111/aphw.12037. Epub 2014 Nov 1.

PMID:
25363863
23.

Poly-dA:dT tracts form an in vivo nucleosomal turnstile.

de Boer CG, Hughes TR.

PLoS One. 2014 Oct 29;9(10):e110479. doi: 10.1371/journal.pone.0110479. eCollection 2014.

24.

Behavioral inhibition errors in Parkinson's disease tested using an antisaccade and antitapping task.

de Boer C, Pel JJ, van den Dorpel JJ, Boon AJ, van der Steen J.

J Parkinsons Dis. 2014;4(4):599-608. doi: 10.3233/JPD-140401.

PMID:
25015545
25.

Field assessment of guar gum stabilized microscale zerovalent iron particles for in-situ remediation of 1,1,1-trichloroethane.

Velimirovic M, Tosco T, Uyttebroek M, Luna M, Gastone F, De Boer C, Klaas N, Sapion H, Eisenmann H, Larsson PO, Braun J, Sethi R, Bastiaens L.

J Contam Hydrol. 2014 Aug;164:88-99. doi: 10.1016/j.jconhyd.2014.05.009. Epub 2014 Jun 4.

PMID:
24963597
26.

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.

Brana I, Calles A, LoRusso PM, Yee LK, Puchalski TA, Seetharam S, Zhong B, de Boer CJ, Tabernero J, Calvo E.

Target Oncol. 2015 Mar;10(1):111-23. doi: 10.1007/s11523-014-0320-2. Epub 2014 Jun 15.

PMID:
24928772
27.

Prognosis and delay of diagnosis among Kaposi's sarcoma patients in Uganda: a cross-sectional study.

De Boer C, Niyonzima N, Orem J, Bartlett J, Zafar SY.

Infect Agent Cancer. 2014 May 20;9:17. doi: 10.1186/1750-9378-9-17. eCollection 2014.

28.

Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial.

Wollmer MA, Kalak N, Jung S, de Boer C, Magid M, Reichenberg JS, Brand S, Holsboer-Trachsler E, Kruger TH.

Front Psychiatry. 2014 Mar 31;5:36. doi: 10.3389/fpsyt.2014.00036. eCollection 2014.

29.

Mini-Mental State Examination subscores indicate visuomotor deficits in Alzheimer's disease patients: A cross-sectional study in a Dutch population.

de Boer C, Mattace-Raso F, van der Steen J, Pel JJ.

Geriatr Gerontol Int. 2014 Oct;14(4):880-5. doi: 10.1111/ggi.12183. Epub 2013 Nov 15.

PMID:
24237759
30.

A unified model for yeast transcript definition.

de Boer CG, van Bakel H, Tsui K, Li J, Morris QD, Nislow C, Greenblatt JF, Hughes TR.

Genome Res. 2014 Jan;24(1):154-66. doi: 10.1101/gr.164327.113. Epub 2013 Oct 29.

31.

Mapping yeast transcriptional networks.

Hughes TR, de Boer CG.

Genetics. 2013 Sep;195(1):9-36. doi: 10.1534/genetics.113.153262. Review.

32.

Repeatability of the timing of eye-hand coordinated movements across different cognitive tasks.

de Boer C, van der Steen J, Schol RJ, Pel JJ.

J Neurosci Methods. 2013 Aug 15;218(1):131-8. doi: 10.1016/j.jneumeth.2013.05.011. Epub 2013 May 31.

PMID:
23732535
33.

A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer.

Heidenreich A, Rawal SK, Szkarlat K, Bogdanova N, Dirix L, Stenzl A, Welslau M, Wang G, Dawkins F, de Boer CJ, Schrijvers D.

Ann Oncol. 2013 Feb;24(2):329-36. doi: 10.1093/annonc/mds505. Epub 2012 Oct 26.

PMID:
23104724
34.

DICER1 RNase IIIb domain mutations are infrequent in testicular germ cell tumours.

de Boer CM, Eini R, Gillis AM, Stoop H, Looijenga LH, White SJ.

BMC Res Notes. 2012 Oct 15;5:569. doi: 10.1186/1756-0500-5-569.

35.

Unique and cross-reactive T cell epitope peptides of the major Bahia grass pollen allergen, Pas n 1.

Etto T, de Boer C, Prickett S, Gardner LM, Voskamp A, Davies JM, O'Hehir RE, Rolland JM.

Int Arch Allergy Immunol. 2012;159(4):355-66. doi: 10.1159/000338290. Epub 2012 Jul 25.

PMID:
22832594
36.

Effectiveness of non-pharmacological interventions for the prevention of bloodstream infections in infants admitted to a neonatal intensive care unit: A systematic review.

Helder O, van den Hoogen A, de Boer C, van Goudoever J, Verboon-Maciolek M, Kornelisse R.

Int J Nurs Stud. 2013 Jun;50(6):819-31. doi: 10.1016/j.ijnurstu.2012.02.009. Epub 2012 Mar 3. Review.

PMID:
22385913
37.

Facing depression with botulinum toxin: a randomized controlled trial.

Wollmer MA, de Boer C, Kalak N, Beck J, Götz T, Schmidt T, Hodzic M, Bayer U, Kollmann T, Kollewe K, Sönmez D, Duntsch K, Haug MD, Schedlowski M, Hatzinger M, Dressler D, Brand S, Holsboer-Trachsler E, Kruger TH.

J Psychiatr Res. 2012 May;46(5):574-81. doi: 10.1016/j.jpsychires.2012.01.027. Epub 2012 Feb 24.

38.

YeTFaSCo: a database of evaluated yeast transcription factor sequence specificities.

de Boer CG, Hughes TR.

Nucleic Acids Res. 2012 Jan;40(Database issue):D169-79. doi: 10.1093/nar/gkr993. Epub 2011 Nov 18.

39.

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.

O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Thompson JA, Gonzalez R, Trefzer U, Mohr P, Ottensmeier C, Chao D, Zhong B, de Boer CJ, Uhlar C, Marshall D, Gore ME, Lang Z, Hait W, Ho P; CNTO 95 Investigators.

Br J Cancer. 2011 Jul 26;105(3):346-52. doi: 10.1038/bjc.2011.183. Epub 2011 Jul 12.

40.

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

Larkin JM, Ferguson TR, Pickering LM, Edmonds K, James MG, Thomas K, Banerji U, Berns B, de Boer C, Gore ME.

Br J Cancer. 2010 Oct 12;103(8):1149-53. doi: 10.1038/sj.bjc.6605889. Epub 2010 Sep 14.

41.

Perseverative and compulsive-like staring causes uncertainty about perception.

van den Hout MA, Engelhard IM, de Boer C, du Bois A, Dek E.

Behav Res Ther. 2008 Dec;46(12):1300-4. doi: 10.1016/j.brat.2008.09.002. Epub 2008 Sep 24.

PMID:
18951122
42.

The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia.

Robinson DW Jr, Eisenberg DF, Cella D, Zhao N, de Boer C, DeWitte M.

J Support Oncol. 2008 Jul-Aug;6(6):283-90. Erratum in: J Support Oncol. 2008 Nov-Dec;6(8):348.

PMID:
18724539
43.

A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.

Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, Caprioni F, Van Cutsem E, Richel D, DeWitte M, Qi M, Robinson D Jr, Zhong B, De Boer C, Lu JD, Prabhakar U, Corringham R, Von Hoff D.

J Support Oncol. 2008 Jan;6(1):18-25.

PMID:
18257397
44.

IGH switch breakpoints in Burkitt lymphoma: exclusive involvement of noncanonical class switch recombination.

Guikema JE, de Boer C, Haralambieva E, Smit LA, van Noesel CJ, Schuuring E, Kluin PM.

Genes Chromosomes Cancer. 2006 Sep;45(9):808-19.

PMID:
16736499
45.

Priapism of the clitoris.

Arntzen BW, de Boer CN.

BJOG. 2006 Jun;113(6):742-3. No abstract available.

46.

Complex biallelic IGH rearrangements in IgM-expressing Z-138 cell line: Involvement of downstream immunoglobulin class switch recombination.

Guikema JE, Fenton JA, de Boer C, Kleiverda K, Brink AA, Raap AK, Estrov Z, Schuuring E, Kluin PM.

Genes Chromosomes Cancer. 2005 Feb;42(2):164-9.

PMID:
15543623
47.

Are surgeons equally satisfied after total knee arthroplasty?

Brokelman RB, Meijerink HJ, de Boer CL, van Loon CJ, de Waal Malefijt MC, van Kampen A.

Arch Orthop Trauma Surg. 2004 Jun;124(5):331-3. Epub 2004 Apr 9.

PMID:
15083311
48.

Fabrication of a glass-implemented microcapillary electrophoresis device with integrated contactless conductivity detection.

Berthold A, Laugere F, Schellevis H, de Boer CR, Laros M, Guijt RM, Sarro PM, Vellekoop MJ.

Electrophoresis. 2002 Oct;23(20):3511-9.

PMID:
12412119
49.

Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.

Verschuuren EA, Stevens SJ, van Imhoff GW, Middeldorp JM, de Boer C, Koëter G, The TH, van Der Bij W.

Transplantation. 2002 Jan 15;73(1):100-4.

PMID:
11792987
50.

Patients at risk for post-transplant lymphoproliferative disease can be identified in the first months after lung transplantation by quantitative-competitive-EBV-PCR.

Verschuuren EA, Stevens S, Hanekamp BB, De Boer C, Harmsen MC, Middeldorp JM, Koeter G, The TH, Van Der Bij W.

J Heart Lung Transplant. 2001 Feb;20(2):199. No abstract available.

PMID:
11250349

Supplemental Content

Loading ...
Support Center